APRI - Apricus Biosciences, Inc.
| Previous Close | 0.41 |
| Open | 0.42 |
| Bid | 0.38 x 4000 |
| Ask | 0.45 x 1900 |
| Day's Range | 0.39 - 0.43 |
| 52 Week Range | 0.25 - 3.34 |
| Volume | 289,307 |
| Avg. Volume | 790,257 |
| Market Cap | 9.376M |
| Beta | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE•19 days ago
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
- ACCESSWIRE•2 months ago
Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON).
- GlobeNewswire•3 months ago
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results:
Company Pursuing U.S. Vitaros Partnership and Strategic Alternatives SAN DIEGO, May 03, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company seeking to advance ...
- GlobeNewswire•3 months ago
Apricus Biosciences Provides Corporate Update and First Quarter 2018 Financial Results
Apricus Biosciences, Inc. (APRI), a biopharmaceutical company seeking to advance innovative medicines in urology and rheumatology, today reported financial results for the first quarter of 2018 and provided a corporate update on its near-term priorities. “Since our recent end-of-review meeting on the NDA for Vitaros with the FDA, we have been focused on pursuing U.S. Vitaros partnership discussions with interested parties. Our objective is to enable continued development and potential approval of the Vitaros product and receive financial terms commensurate with this development stage asset in exchange for a sublicense or assignment of our U.S. development and/or commercialization rights. In parallel, the Company is evaluating strategic alternatives, which may include a sale of the company, a business combination, a merger or reverse merger or a license, and in order to maximize shareholder value, the Company has engaged Canaccord Genuity LLC to assist in that process,” said Richard Pascoe, Chief Executive Officer.
- GlobeNewswire•3 months ago
Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, ...
- GlobeNewswire•4 months ago
Apricus Biosciences Announces Pricing of $3.55 Million Public Offering
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
- GlobeNewswire•4 months ago
Apricus Biosciences Announces Proposed Public Offering
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has ...
- GlobeNewswire•4 months ago
Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA
Meeting Scheduled for April 12, 2018 SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ...
- ACCESSWIRE•4 months ago
Apricus Biosciences, Vitaros Update, The ED Market, Analysts Target Price, Pipeline
NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
- ACCESSWIRE•4 months ago
Blog Exposure - Cipher to Acquire Cardiome’s Canadian Business Portfolio for $25.5 Million in Cash
Stock Monitor: Apricus Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 22, 2018 / Active-Investors.com has just released a free research report on Cardiome Pharma Corp. (NASDAQ: CRME ...
- GlobeNewswire•5 months ago
Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results
Company Expects to Submit Vitaros End of Review Meeting Request This Month Vitaros End-of-Review Meeting Expected to Occur in April 2018 Company Expects Cash Runway Through 2018 Conference Call / Webcast ...
- ACCESSWIRE•5 months ago
Apricus Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Apricus Biosciences, Inc. (NASDAQ: APRI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 4:30 PM Eastern ...
- GlobeNewswire•5 months ago
Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call
SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company`s ...
- GlobeNewswire•5 months ago
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines ...
- ACCESSWIRE•8 months ago
SeeThruEquity Issues Update Note on Apricus Biosciences, Inc. (Nasdaq CM: APRI) with Target Price of $4.30
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has ...
- GlobeNewswire•9 months ago
Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call
SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus` ...